Daximendan

Daximendan (containing Levosimendan) is a calcium sensitizer and potassium channel opener. It increases cardiac contractility without increasing intracellular calcium, and causes vasodilation, thereby reducing both preload and afterload.

Dosage by Body Weight

For intravenous use only. Must be administered in a specialized hospital setting under continuous monitoring. Typically initiated with an intravenous loading dose of 6-12 mcg/kg over 10 minutes, followed by a continuous infusion of 0.05-0.2 mcg/kg/min for 24 hours.

  1. Body Weight
    Below 5 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Safety and efficacy in pediatric patients have not been established.
  2. Body Weight
    5-7 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Safety and efficacy in pediatric patients have not been established.
  3. Body Weight
    8-10 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Safety and efficacy in pediatric patients have not been established.
  4. Body Weight
    11-15 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Safety and efficacy in pediatric patients have not been established.
  5. Body Weight
    16-20 kg
    Dose
    Not recommended
    Frequency
    N/A
    Tracking Notes
    Safety and efficacy in pediatric patients have not been established.

Formulation

Intravenous Infusion

Purpose

Short-term treatment of acutely decompensated severe chronic heart failure (ADHF) when conventional therapy is insufficient.

Generic Name

Levosimendan

Scheduled Drug

Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.

Alternatives

SimdaxDobutamineMilrinone

Disclaimer: This information is for educational purposes only. WHO references and weight bands are simplified for tracking and must not replace medical advice. Always consult with a healthcare professional before starting or changing any medication.